KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Current Assets: 2009-2025

Historic Current Assets for Arbutus Biopharma (ABUS) over the last 15 years, with Sep 2025 value amounting to $97.4 million.

  • Arbutus Biopharma's Current Assets fell 26.61% to $97.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $97.4 million, marking a year-over-year decrease of 26.61%. This contributed to the annual value of $127.3 million for FY2024, which is 3.57% down from last year.
  • As of Q3 2025, Arbutus Biopharma's Current Assets stood at $97.4 million, which was down 5.51% from $103.1 million recorded in Q2 2025.
  • Arbutus Biopharma's Current Assets' 5-year high stood at $172.7 million during Q1 2022, with a 5-year trough of $83.5 million in Q2 2021.
  • For the 3-year period, Arbutus Biopharma's Current Assets averaged around $131.5 million, with its median value being $132.8 million (2024).
  • Per our database at Business Quant, Arbutus Biopharma's Current Assets skyrocketed by 89.05% in 2022 and then slumped by 30.43% in 2025.
  • Arbutus Biopharma's Current Assets (Quarterly) stood at $160.7 million in 2021, then decreased by 5.93% to $151.1 million in 2022, then fell by 12.65% to $132.0 million in 2023, then fell by 3.57% to $127.3 million in 2024, then fell by 26.61% to $97.4 million in 2025.
  • Its Current Assets stands at $97.4 million for Q3 2025, versus $103.1 million for Q2 2025 and $116.8 million for Q1 2025.